email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
2716 - 2730
of 3630 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
Next
Cellular Bio Acquires Rights to Solid Tumor Immunotherapy from National Cancer Institute
$5.00
Available
Go Therapeutics Signs $195 Million Licensing Deal with Roche
$5.00
Available
HiFiBiO Forms Cell Therapy Discovery Collaboration with Kite Pharma
$5.00
Available
CANbridge Files to Start Clinical Trials of Breast Cancer Drug in China
$5.00
Available
Fosun Pharma Officially Announces Plan for Henlius Hong Kong IPO
$5.00
Available
Shanghai Aohua Endoscopy Completes $44 Million Series D Funding
$5.00
Available
Innovent Approved to Start US Clinical Trial of CD47 Immunotherapy
$5.00
Available
ACEA, a US-China Cell Analysis Device Company, Acquired for $250 Million
$5.00
Available
Bellen Chemistry of Beijing, a CRO/CMO, Raises $30 Million-Plus in C Round
$5.00
Available
Fosun Pharma Acquires China Rights to Stroke Drug in $32.5 Million Agreement
$5.00
Available
CSPC Acquires China Rights to Verastem Cancer Drug in $45 Million Deal
$5.00
Available
WuXi Biologics Collaborates with I-Mab to Develop Three BiSpecifics
$5.00
Available
Flow Pharma Forms JV with Button Capital for China Clinical Trials
$5.00
Available
Everest Acquires China/Asia Rights to VenatoRx Drug-Resistant Anti-Infective
$5.00
Available
Zhejiang Anglikang Pharma Approved for $87 Million IPO in Shenzhen
$5.00
Available